文献速递痛风与晶体性关节病

甲氨蝶呤提高接受培戈洛酶治疗的未控制痛风患者应答率的随机安慰剂对照研究:主要疗效与安全性结果

A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings.
PubMed 文献 · Arthritis Rheumatol · 2022-12-16

这项随机、安慰剂对照、双盲试验纳入152例未控制痛风患者,按2:1随机接受培戈洛酶联合甲氨蝶呤(MTX)或培戈洛酶联合安慰剂治疗52周。第6个月治疗应答率MTX组为71.0%(71/100),安慰剂组为38.5%(20/52),组间差异32.3%(95%CI 16.3%, 48.3%),P<0.0001。MTX联合治疗还降低了输液反应发生率和抗药抗体阳性率,未发现新的安全性信号。

要点

  • 第6个月治疗应答率MTX组71.0% vs 安慰剂组38.5%,组间差异32.3%(95%CI 16.3%, 48.3%),P<0.0001。
  • 输液反应发生率MTX组4.2%(4/96,含1例过敏反应)vs 安慰剂组30.6%(15/49,0例过敏反应),P<0.001。
  • MTX组抗药抗体阳性率低于安慰剂组,两组不良事件和严重不良事件报告相当。

核心结论

  • MTX联合治疗使培戈洛酶的应答率显著高于安慰剂(71.0% vs 38.5%),且未发现新的安全性信号。
  • 研究结果证实培戈洛酶与MTX联合给药时治疗应答率更高、输液反应发生率更低、免疫原性更低。

研究设计与样本

  • 随机、安慰剂对照、双盲试验,纳入未控制痛风成人患者,定义为血清尿酸≥7 mg/dl、口服降尿酸治疗失败或不耐受、且存在持续痛风症状包括≥1个痛风石、过去12个月≥2次发作或痛风性关节炎。
  • 关键排除标准包括MTX禁忌、当前使用免疫抑制剂、G6PDH缺乏、估算肾小球滤过率<40 ml/min/1.73 m2。
  • 患者按2:1随机接受52周培戈洛酶(8 mg,每两周一次)联合口服MTX(15 mg/周)或安慰剂。
  • 主要终点为第6个月期间治疗应答者比例,定义为第20-24周期间≥80%的访视血清尿酸<6 mg/dl。
  • 疗效在意向治疗人群(所有随机患者)中评估,安全性在所有接受≥1次盲法MTX或安慰剂剂量的患者中评估。

主要发现

  • 共152例患者随机分组,100例接受培戈洛酶联合MTX,52例接受培戈洛酶联合安慰剂。
  • 第6个月治疗应答率MTX组为71.0%(71/100),安慰剂组为38.5%(20/52),组间差异32.3%(95%CI 16.3%, 48.3%),组间差异P<0.0001。
  • 前6个月治疗期间,MTX组96例中78例(81.3%)vs 安慰剂组49例中47例(95.9%)发生≥1次不良事件,最常见为痛风发作(MTX组96例中64例[66.7%] vs 安慰剂组49例中34例[69.4%])。
  • 输液反应发生率MTX联合治疗组为4.2%(96例中4例,包括1例过敏反应),安慰剂联合治疗组为30.6%(49例中15例,0例过敏反应),P<0.001。
  • MTX组抗药抗体阳性率也低于安慰剂组。

关键数值与推荐

  • 未控制痛风定义:血清尿酸≥7 mg/dl,口服降尿酸治疗失败或不耐受,且存在持续痛风症状包括≥1个痛风石、过去12个月≥2次发作或痛风性关节炎。
  • 主要终点治疗应答定义:第20-24周期间≥80%的访视血清尿酸<6 mg/dl。
  • 培戈洛酶给药方案:8 mg,每两周一次,联合口服MTX 15 mg/周或安慰剂,治疗52周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess efficacy, safety, pharmacokinetics, and immunogenicity of pegloticase plus methotrexate (MTX) versus pegloticase plus placebo cotreatment for uncontrolled gout in a randomized, placebo-controlled, double-blind trial. METHODS: This study included adults with uncontrolled gout, defined as serum urate ≥7 mg/dl, oral urate-lowering therapy failure or intolerance, and presence of ongoing gout symptoms including ≥1 tophus, ≥2 flares in the past 12 months, or gouty arthritis. Key exclusion criteria included MTX contraindication, current immunosuppressant use, G6PDH deficiency, and estimated glomerular filtration rate <40 ml/minute/1.73 m2 . Patients were randomized 2:1 to 52 weeks of pegloticase (8 mg biweekly) with either oral MTX (15 mg/week) or placebo. The primary end point was the proportion of treatment responders during month 6 (defined as serum urate <6 mg/dl for ≥80% of visits during weeks 20-24). Efficacy was evaluated in all randomized patients (intent-to-treat population), and safety was evaluated in all patients receiving ≥1 blinded MTX or placebo dose. RESULTS: A total of 152 patients were randomized, 100 to receive pegloticase plus MTX, 52 to receive pegloticase plus placebo. Significantly higher treatment response occurred during month 6 in the MTX group versus the placebo group (71.0% [71 of 100 patients] versus 38.5% [20 of 52 patients], respectively; between-group difference 32.3% [95% confidence interval 16.3%, 48.3%]) (P < 0.0001 for between-group difference). During the first 6 months of pegloticase plus MTX or pegloticase plus placebo treatment, 78 (81.3%) of 96 MTX patients versus 47 (95.9%) of 49 placebo patients experienced ≥1 adverse event (AE), most commonly gout flare (64 [66.7%] of 96 MTX patients and 34 [69.4%] of 49 placebo patients). Reports of AEs and serious AEs were comparable between groups, but the infusion reaction rate was considerably lower with MTX cotherapy (4.2% [4 of 96 MTX patients, including 1 patient who had anaphylaxis]) than with placebo cotherapy (30.6% [15 of 49 placebo patients, 0 who had anaphylaxis]) (P < 0.001). Antidrug antibody positivity was also lower in the MTX group. CONCLUSION: MTX cotherapy markedly increased pegloticase response rate over placebo (71.0% versus 38.5%) during month 6 with no new safety signals. These findings verify higher treatment response rate, lower infusion reaction incidence, and lower immunogenicity when pegloticase is coadministered with MTX.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Botson JK, Saag K, Peterson J, et al. A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings. Arthritis Rheumatol. 2022. PMID: 36099211. doi:10.1002/art.42335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。